- Home
- WETH vs CANF Comparison
WETH vs CANF Comparison
Compare WETH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WETH
- CANF
- Stock Information
- Founded
- WETH 1992
- CANF 1994
- Country
- WETH China
- CANF Israel
- Employees
- WETH N/A
- CANF N/A
- Industry
- WETH
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- WETH
- CANF Health Care
- Exchange
- WETH Nasdaq
- CANF Nasdaq
- Market Cap
- WETH 10.9M
- CANF 9.6M
- IPO Year
- WETH N/A
- CANF N/A
- Fundamental
- Price
- WETH $1.49
- CANF N/A
- Analyst Decision
- WETH
- CANF Strong Buy
- Analyst Count
- WETH 0
- CANF 2
- Target Price
- WETH N/A
- CANF $14.50
- AVG Volume (30 Days)
- WETH 245.1K
- CANF 185.6K
- Earning Date
- WETH 11-13-2025
- CANF 11-27-2025
- Dividend Yield
- WETH N/A
- CANF N/A
- EPS Growth
- WETH N/A
- CANF N/A
- EPS
- WETH 0.71
- CANF N/A
- Revenue
- WETH $42,692,692.00
- CANF $560,000.00
- Revenue This Year
- WETH N/A
- CANF $461.72
- Revenue Next Year
- WETH N/A
- CANF N/A
- P/E Ratio
- WETH $1.96
- CANF N/A
- Revenue Growth
- WETH 6.48
- CANF N/A
- 52 Week Low
- WETH $0.76
- CANF $0.58
- 52 Week High
- WETH $2.85
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- WETH 70.23
- CANF 35.50
- Support Level
- WETH $1.16
- CANF $0.59
- Resistance Level
- WETH $1.77
- CANF $0.64
- Average True Range (ATR)
- WETH 0.15
- CANF 0.02
- MACD
- WETH 0.00
- CANF 0.00
- Stochastic Oscillator
- WETH 48.30
- CANF 12.75
About WETH Wetouch Technology Inc.
Wetouch Technology Inc is a touch panel supplier focused on R & D, production and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots and charging stations. The company sells touchscreen products both domestically in China and internationally, covering the majority of areas in China, Taiwan, South Korea, and Germany.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).